Niraparib Approved for Frontline Maintenance: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

The FDA has now expanded the approval of niraparib (Zejula®, GlaxoSmithKline) to include maintenance therapy for adults with metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. This frontline maintenance approval adds to previous approvals for third-line or later maintenance therapy in these cancers regardless of HRD...
Continue reading

Niraparib Approved for Advanced HRD-Positive Ovarian Cancer

The FDA has approved niraparib (Zejula®, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who experience disease progression following three or more lines of chemotherapy. Niraparib is indicated for patients whose tumors are positive for homologous recombination deficiency (HRD). The approval was based on QUADRA (NCT02354586), a multicenter, open-label, single-arm, phase 2 trial that enrolled 463 patients with relapsed, high-grade serous epithelial o...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Regarding PARP Inhibitor Therapies

Poly(ADP)-ribose polymerase (PARP) inhibition is a new form of targeted therapy that has exhibited effectiveness in treating several solid tumor types. Olaparib (Lynparza®, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula®, Tesaro) have all been approved for the treatment of advanced ovarian cancer. Olaparib has also been approved to treat BRCA-mutated breast cancer and is currently being investigated in the treatment of prostate cancer. Another PARP inhibitor, talazopa...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.